Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Cisplatin 75mg/m2
DRUG
2 trials
Sponsors
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
, Inhibrx Biosciences, Inc
Conditions
Gastric Cancer
Head and Neck Cancer
Melanoma
NSCLC
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Solid Tumor
Urothelial Carcinoma
Phase 1
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Active, not recruiting
NCT04198766
Inhibrx Biosciences, Inc
Gastric Cancer, Head and Neck Cancer, Melanoma +4
Start: 2019-12-10
End: 2027-05-12
Updated: 2025-12-18
Phase 3
A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Withdrawn
NCT03058094
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
NSCLC
Start: 2018-12-31
End: 2020-01-31
Updated: 2019-02-04
Related Papers
INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058
The Journal of Immunology
2025-11-01
HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.
Journal of Clinical Oncology
2025-05-28
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
Journal for ImmunoTherapy of Cancer
2025-05-01
4 citations
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Regular and Young Investigator Award Abstracts
2023-10-31
1 citations
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
Regular and Young Investigator Award Abstracts
2023-10-31
856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors
Regular and Young Investigator Award Abstracts
2021-11-01
9 citations